AdairF., BergJ., JoubertL., RobbinsG.F.: Long-term follow up of breast cancer patients: the 30-year report.Cancer, 33: 1145–1150, 1974.
2.
AmadoriD., NanniO., MarangoloM., PaciniP., RavaioliA., RossiA., GambiA., CatalanoG., PerroniD., ScarpiE., GiunchiD.C., TienghiA., BeccioliniA., VolpiA.: Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapidly proliferating breast cancer: a randomised multicenter study.J. Clin. Oncol., 18: 3125–3134, 2000.
3.
ASCO Expert Panel:1997 update of recommendation for the use of tumor markers in breast and colorectal cancer.J. Clin. Oncol., 16: 793–795, 1997.
4.
ASCO Expert Panel:Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer: report of the American Society of Clinical Oncology Expert Panel.J. Clin. Oncol., 14: 2843–2877, 1996.
5.
BonadonnaG., ValagussaP., ZambettiM., BuzzoniR., MoliterniA.: Milan adjuvant trials for stage I-II breast cancer. In SalmonSE (Ed.): Adjuvant Therapy of Cancer, Orlando, Grune & Stratton, pp. 211–221, 1987.
6.
Castiglione-GertschM., PriceK.N., NasiM.L.: Is the addition of adjuvant chemotherapy always necessary in node negative (N-) postmenopausal breast cancer patients (pts) who receive tamoxifen (TAM)?: first results of IBCSG trial IX.Proc ASCO,19: 73a abs 281, 2000.
7.
ClarkG.M.: Prognostic and predictive factors. In: Disease of the breast,HarrisJ.R., LippmannM.E., MorrowM., HellmannS. (Eds.), Lippincott-Raven Publishers, Philadelphia, New York, p. 463 and p. 470, 1996.
8.
CollinsR., GrayR., GodwinJ., PetoR.: Avoidance of large biases and large random errors in the assessment of moderate treatment effects: the need for systematic overviews.Stat. Med.,6: 245, 1987.
9.
Early Breast Cancer Trialist’ Collaborative Group:Poly-chemotherapy for early breast cancer: an overview of the randomised trials.Lancet, 352: 930–942, 1998.
10.
Early Breast Cancer Trialist’ Collaborative Group:Tamoxifen for early breast cancer: an overview of the randomised trials.Lancet, 351: 1451–1467, 1998.
11.
FisherB., AndersonS., WolmarkN., Tan-ChiuE.: Chemotherapy with or without tamoxifen for patients with ER negative breast cancer and negative nodes: results from NSABP B23.Proc. ASCO,19: 72a (abstr. 277), 2000.
12.
FisherB., CostantinoJ., RedmondC., PoissonR., BowmanD., CoutureJ., DimitrovN.V., WolmarkN., WickerhamD.L., FisherE.R.: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors.N. Engl. J. Med., 320: 479–484, 1989.
13.
FisherB., DignanJ., WolmarkN., De CillisA., EmirB., WickersmanD.L., BryantJ., DimitrovN.V., AbramsonN., AtkinsJ.N., ShibataH., DeschenesL., MargoleseR.G.: Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.J. Natl. Cancer Inst., 89: 1673–1682, 1997.
14.
FisherB., RedmondC., DimitrovN.: A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node negative breast cancer who have estrogen-receptor-negative tumors.N. Engl. J. Med., 320: 479–484, 1989.
15.
GoldhirschA., GlickJ.H., GelberR., SennH.J.: Meeting highlights: International Consensus Panel on the treatment of primary breast cancer.J. Natl. Cancer Inst., 90: 1601–1608, 1998.
16.
HarrisI.R., HellmanS.: Natural history of breast cancer. In: Disease of the breast,HarrisJ.R., LippmannM.E., MorrowM. (Ed.), Lippincott-Raven, Philadelphia PA, pp. 375–391, 1996.
JakeszR., KolbR., ReinerG.: Adjuvant chemotherapy in node negative breast cancer patients. In: Adjuvant therapy of cancer,SalmonS.E. (Ed.), Grune & Stratton, Orlando, pp. 223–231, 1987.
19.
Ludwig Breast Cancer Study Group.Prolonged disease free survival after one course of perioperative adjuvant chemotherapy for node negative breast cancer.N. Engl. I. Med., 320: 491–496, 1989
20.
MansourE.G., GrayR., ShatilaA.H.Efficacy of adjuvant chemotherapy in high risk node negative breast cancer.N. Engl. I. Med., 320: 485–490, 1989
21.
McNeilC.: In early breast cancer, who does not need chemo? The hunt for prognostic markers.I. Natl. Cancer Inst., 90: 1594–1596, 1998.
22.
MorrisonJ.M., HowellA., GrieveR.J.: The West Midlands Oncology Association trials of adjuvant chemotherapy for operable breast cancer. In: Adjuvant therapy of cancer,SalmonS.E. (Ed.), Grune & Stratton, Orlando, pp. 311–318, 1987.
23.
National Cancer Institute.Treatment Alert issued for node-negative breast cancer.J. Natl. Cancer Inst., 80: 550–551, 1988.
24.
Nolvadex Adjuvant Trial Organisation:Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer.Br J. Cancer57: 608–611, 1988.
25.
PetoR., PikeM.C., ArmitageP., CoxD.R., HowardS.V., MantelN., McPhersonK., PetoJ., SmithP.G.: Design and analysis of randomised clinical trials requiring prolonged observation of each patient.Br. J. Cancer, 34: 585–612, 1976 and35: 1–39, 1977.
26.
RavdinP.M., SiminoffI.A., HarveyJ.A.: Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy.J. Clin. Oncol., 16: 515–521, 1998.
27.
RosenP.P., GroshenS., SaigoP.E., KinneD.W., HellmanS.: A long term follow up study of survival in stage I (T1N0M0) and stage II (T1N2M0) breast carcinoma.J. Clin. Oncol., 7: 355–366, 1989.
28.
Scottish Cancer Trials Office:Adjuvant tamoxifen in the management of operable breast cancer: The Scottish Trial.Lancet, 2: 171–175, 1987.
29.
SemiglazovV.F., BavliJ.C., MoiseyenkoV.M., RzhankovS.V., MigmanovaN.S., PopovaR.T., SeleznyovI.K., KremenB.V., KostetskayaT.V., BarashN.J.: Clinical trials on adjuvant chemotherapy for breast cancer.Cancer, 57: 1957–1960, 1985.
30.
ThomssenC., JanickeF.: Do we need better prognostic factors in node-negative breast cancer?Pro. Eur. J. Cancer, 36: 293–306, 2000.
31.
Treatment of early stage breast cancer.NIH Consensus Dev., Conf. Consensus Statement, 8, 1990.
32.
YounesM., LauciricaR.: Lack of prognostic significance of histological grade in node negative invasive breast carcinoma.Clin. Cancer Res., 3: 601–604, 1997.
